CompletedNCT01417507
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Ali Choucair, MDRadiation Therapy Oncology Group
- Intervention
- cognitive assessment(procedure)
- Enrollment
- 82 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2014
Study locations (30)
- The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Providence Hospital, Mobile, Alabama, United States
- Arizona Oncology Services Foundation, Phoenix, Arizona, United States
- Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- Florida Hospital, Orlando, Florida, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- University of Hawaii, Honolulu, Hawaii, United States
- Hawaii Medical Center East, Honolulu, Hawaii, United States
- Leeward Radiation Oncology Center, ‘Ewa Beach, Hawaii, United States
- Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States
- Covenant Medical Center, Waterloo, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01417507 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco